BioCity Biopharma, a Chinese biotechnology company, has announced the completion of enrollment for all 120 subjects in the Phase II clinical study for its small molecule ETA receptor antagonist, SC0062, in the IgA nephropathy cohort. The study, which first dosed in June 2023, marks a significant milestone in the development of this potential treatment for chronic kidney disease.
SC0062 is recognized as one of the top three ETA receptor small molecule antagonists in clinical practice globally for the treatment of chronic kidney disease. It has undergone a novel molecular design tailored for chronic kidney disease, boasting unique ETA high selectivity. This design aims to enhance drug safety while maintaining efficacy. Preclinical studies have demonstrated that SC0062 exhibits good activity and can effectively improve the pathological scores in models of acute kidney injury and chronic kidney disease. The completed Phase I study showed that SC0062 has good safety, tolerability, and pharmacokinetics, with no observed side effects such as water and sodium retention.
Currently, SC0062 is in a Phase II clinical study for chronic kidney disease with proteinuria. This multicenter, randomized, double-blind, placebo-controlled study includes two cohorts: the diabetes nephropathy cohort and the IgA nephropathy cohort. The study is designed to assess the efficacy and safety of SC0062 in patients with chronic kidney disease who present with proteinuria.
The completion of enrollment in the IgA nephropathy cohort brings BioCity Biopharma one step closer to potentially offering a new therapeutic option for patients suffering from chronic kidney disease.- Flcube.com
